Document is current
Any future updates will be listed below
-
Authors
Luptak, Jakub
Clift, Dean
Mukadam, Aamir
Benn, Jonathan
Rhinesmith, Tyler https://orcid.org/0000-0002-9983-0287
McLaughlin, Stephen H. https://orcid.org/0000-0001-9135-6253
Dodds, Amy C.
Lapetaje, Jerson E.
Sczaniecka-Clift, Matylda
France, David J. https://orcid.org/0000-0002-5409-3316
McEwan, William A. https://orcid.org/0000-0002-4408-0407
James, Leo C. https://orcid.org/0000-0003-2131-0334
-
Funding
Funding for this research was provided by:
Wellcome Trust (223054/Z/21/Z)
- License Information
-
More Information
Article History
Received: 20 June 2025
Accepted: 16 October 2025
First Online: 25 November 2025
Competing interests
: The authors declare the following competing interests: JL, DC, DJF and LCJ are inventors on a related patent application. WIPO (PCT) application filed by UKRI, inventors LCJ, DJF, DC and JL, WO2025021697A1, published 2025-01-30, PCT stage, covers MRC36-38. LCJ and WAM are co-founders of TRIMTECH Therapeutics, and DC and JB are TRIMTECH Therapeutics employees. TRIMTECH Therapeutics is a TRIMTAC protein degradation company. The remaining authors declare no competing interests.
